Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
← catalyst calendarSponsored by Creative Medical Technology Holdings Inc (industry) · CELZ — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
45estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-21 | actual | When the study began enrolling |
| Primary completion | 2026-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Low-back Pain
- Degenerative Disc Disease
Interventions
- Drug: CELZ-201-DDT
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFEvaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.
measured 6 months
Permalink · CELZ's whole pipeline · Catalyst calendar · Every registered study · What changed